1 – 6 of 6
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2010
-
Mark
European Association of Urology. Position statement on screening for prostate cancer
- Contribution to journal › Debate/Note/Editorial
- 2008
-
Mark
Clinical proof of concept study (blossom) shows novel beta 3 adrenoceptor agonist YM178 is effective and well tolerated in the treatment of symptoms of overactive bladder
(2008) 23rd Annual Congress of the European Association of Urology, 2008 In European Urology Supplements 7(3). p.239-239
- Contribution to journal › Published meeting abstract
- 2006
-
Mark
Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder
Abrams, P ; Andersson, Karl-Erik LU
; Buccafusco, JJ
; Chapple, C
; de Groat, WC
; Fryer, AD
; Kay, G
; Laties, A
; Nathanson, NM
and Pasricha, PJ
, et al.
(2006)
In British Journal of Pharmacology
148(5).
p.565-578
- Contribution to journal › Scientific review
- 2005
-
Mark
Nocturia: morbidity and management in adults
Wagg, A ; Andersson, Karl-Erik LU
; Cardozo, L
; Chapple, C
; Kirby, M
; Kelleher, C
; Lose, G
and Milsom, I
(2005)
In International Journal of Clinical Practice
59(8).
p.938-945
- Contribution to journal › Scientific review
- 2002
-
Mark
Tamsulosin: an overview
- Contribution to journal › Article
-
Mark
Future drugs for the treatment of benign prostatic hyperplasia.
Andersson, Karl-Erik LU
; Chapple, C R
and Höfner, K
(2002)
In World Journal of Urology
19(6).
p.436-442
- Contribution to journal › Article